FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.

Abstract

FAMTX is at least as active as EAP and is significantly less toxic. Although both regimens remain investigational, the toxicities of FAMTX are more manageable. Further studies involving FAMTX in both the adjuvant and advanced disease setting are underway.